Phase 3 Clinical Trials With Primary Completion Dates in October 2023
This is a list of Phase 3 trials with primary completion dates in October 2023 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
|Symbol||Company||Primary Completion Date||Phase||NCT ID||Title|
|APLMW||Apollomics, Inc.||2023-10-01||Phase 3||NCT05054543||Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AML|
|ARDS||Aridis Pharmaceuticals, Inc.||2023-10-01||Phase 3||NCT05331885||A Human Monoclonal Antibody Against Staphylococcus Aureus Alpha Toxin in Mechanically Ventilated Adult Subjects - 2|
|BLCO||Bausch + Lomb Corporation||2023-10-01||Phase 3||NCT05360784||"Efficacy and Safety of Brimonidine Tartrate Preservative-Free Formulation in Adults With Ocular Redness"|
|CHHE||China Health Industries Holdings, Inc.||2023-10-01||Phase 3||NCT04522102||Antiplatelet Secondary Prevention International Randomised Trial After INtracerebral haemorrhaGe (ASPIRING)-Pilot Phase|
|CORT||Corcept Therapeutics Incorporated||2023-10-01||Phase 3||NCT04308590||Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas|
|EIGR||Eiger BioPharmaceuticals, Inc.||2023-10-01||Phase 3||NCT04727424||Repurposed Approved and Under Development Therapies for Patients With Early-Onset COVID-19 and Mild Symptoms|
|ITCI||Intra-Cellular Therapies, Inc.||2023-10-01||Phase 3||NCT05061706||Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder|
|TNXP||Tonix Pharmaceuticals Holding Corp.||2023-10-01||Phase 3||NCT05273749||A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily in Patients With Fibromyalgia|